Abstract
In the last years the advances in NGS technology have improved the knowledge of the tumor molecular profile in different neoplasias. The detection of biomarkers as predictors of treatment response or identification of targeted therapies allow individualize treatments. Indeed, identifying patients with specific genomic alteration has relevant clinical implications. A problem to solve is the low availability of tumor sample in patients with lung cancer. Therefore, the possibility to analyse the circulating tumor DNA (ctDNA) in blood sample as a complementary diagnosis method is really important to consider in the near future.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
